Hepatocellular carcinoma: Initial tumour response after short-term and long-interval chemoembolization with drug-eluting beads using modified RECIST

European Journal of Gastroenterology and Hepatology

Volumn 24, Issue 11, 2012, Pages 1325-1332

  Syha, Roland ^a   Ketelsen, Dominik ^a   Heller, Stefan ^a   Schmehl, Jörg ^a   Mangold, Stefanie ^a   Heuschmid, Martin ^a   Springer, Fabian ^a   Claussen, Claus D ^a   Brechtel, Klaus ^a  

^a UNIVERSITY OF TÜBINGEN   (Germany)

Author keywords

Drug eluting beads; Hepatocellular carcinoma; Modified Response Evaluation Criteria in the Solid Tumours; Transarterial chemoembolization; Tumour response

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; GAMMA GLUTAMYLTRANSFERASE;

ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CANCER CLASSIFICATION; CANCER GROWTH; CHEMOEMBOLIZATION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG ELUTING STENT; FEMALE; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; HUMAN; LIVER CELL CARCINOMA; MALE; MODIFIED RESPONSE EVALUATION CRITERIA IN SOLID TUMORS; MULTIDETECTOR COMPUTED TOMOGRAPHY; NUCLEAR MAGNETIC RESONANCE IMAGING; PRACTICE GUIDELINE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TRANSARTERIAL CHEMOEMBOLIZATION; TREATMENT RESPONSE;

ADULT; AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; FEMALE; HUMANS; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TIME FACTORS; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME; TUMOR BURDEN;

EID: 84867337650     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/MEG.0b013e32835724bc     Document Type: Article

References (31)

1. Achenbach T, Seifert JK, Pitton MB, Schunk K, Junginger T. Chemoembolization for primary liver cancer. Eur J Surg Oncol 2002; 28:37-41. (Pubitemid 41122780)
2. Llovet JM, Di Bisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, et al. Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl CancerInst2008; 100:698-711.
3. Llovet JM, Bru C, Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 1999; 19:329-338.
4. Lencioni R, Paolicchi A, Moretti M, Pinto F, Armillotta N, Di Giulio M, etal. Combined transcatheter arterial chemoembolization and percutaneous ethanol injection for the treatment of large hepatocellular carcinoma: local therapeutic effect and long-term survival rate. Eur Radiol1998; 8:439-444. (Pubitemid 128546251)
5. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005; 40:225-235. (Pubitemid 40613379)
6. Veltri A, Moretto P, Doriguzzi A, Pagano E, Carrara G, Gandini G. Radiofrequency thermal ablation (RFA) after transarterial chemoembolization (TACE) as a combined therapy for unresectable non-early hepatocellular carcinoma (HCC). Eur Radiol 2006; 16:661-669. (Pubitemid 44149378)
7. Bargellini I, Vignali C, Cioni R, Petruzzi P, Cicorelli A, Campani D, et al. Hepatocellular carcinoma: CT for tumor response after transarterial chemoembolization in patients exceeding Milan criteria - selection parameter for liver transplantation. Radiology 2010; 255:289-300.
8. Elia C, Venon WD, Stradella D, Martini S, Brunello F, Marzano A, et al. Transcatheter arterial chemoembolization for hepatocellular carcinoma in cirrhosis: influence on portal hypertension. Eur J Gastroenterol Hepatol 2011; 23:573-577.
9. Llovet JM, Real MI, Montana X, Planas R, Coll S, Aponte J, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet 2002; 359:1734-1739. (Pubitemid 34607087)
10. Lo CM, Ngan H,Tso WK, Liu CL, Lam CM, Poon RT, etal. Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology 2002; 35:1164-1171. (Pubitemid 34454013)
11. Vogl TJ, Zangos S, Balzer JO, Nabil M, Rao P, Eichler K, et al. Transarterial chemoembolization (TACE) in hepatocellular carcinoma: technique, indication and results. RoFo 2007; 179:1113-1126. (Pubitemid 350155118)
12. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc J-F, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008; 359:378-390.
13. Peck-Radosavljevic M, Greten TF, Lammer J, Rosmorduc O, Sangro B, Santoro A, et al. Consensus on the current use of sorafenib for the treatment of hepatocellular carcinoma. Eur J Gastroenterol Hepatol 2010; 22:391-398.
14. Dhanasekaran R, Kooby DA, Staley CA, Kauh JS, Khanna V, Kim HS. Comparison of conventional transarterial chemoembolization (TACE) and chemoembolization with doxorubicin drug eluting beads (DEB) for unresectable hepatocelluar carcinoma (HCC). J Surg Oncol 2010; 101:476-480.
15. Lammer J, Malagari K, Vogl T, Pilleul F, Denys A, Watkinson A, et al. Prospective randomized study of doxorubicin-eluting-bead embolization in the treatment of hepatocellular carcinoma: results of the PRECISION V study. Cardiovasc Intervent Radiol 2010; 33:41-52.
16. Song MJ, Park C-H, Kim JD, Kim HY, Bae SH, Choi JY, et al. Drug-eluting bead loaded with doxorubicin versus conventional Lipiodol-based transarterial chemoembolization in the treatment of hepatocellular carcinoma: a case-control study of Asian patients. Eur J Gastroenterol Hepatol 2011; 23:521-527.
17. Vogl TJ, Lammer J, Lencioni R, Malagari K, Watkinson A, Pilleul F, et al. Liver, gastrointestinal, and cardiac toxicity in intermediate hepatocellular carcinomatreated with PRECISION TACEWith Drug-Eluting Beads: results from the PRECISION V randomized trial. Am J Roentgenol 2011; 197:562-570.
18. Chen RC, Lii JM, Chen WT, Tu HY, Chiang LC. Transcatheter arterial chemoembolization in patients with hepatocellular carcinoma and coexisting hepatic cavernous hemangioma. Eur Radiol 2006; 16:1346-1350.
19. Ebied OM, Federle MP, Carr BI, Pealer KM, Li W, Amesur N, etal. Evaluation of responses to chemoembolization in patients with unresectable hepatocellular carcinoma. Cancer 2003; 97:1042-1050. (Pubitemid 36173156)
20. Herber SC, Otto G, Woerns M, Moench C, Kanzler S, Junginger T, et al. Single center experience over a 5-year period with sequential transarterial chemoembolization (TACE) in the treatment of hepatocellular carcinoma (HCC). RoFo 2007; 179:289-299. (Pubitemid 46769331)
21. Kamath PS, Kim WR. The model for end-stage liver disease (MELD). Hepatology 2007; 45:797-805. (Pubitemid 46450631)
22. Yan P, Yan LN. Staging of hepatocellular carcinoma. Hepatobiliary Pancreat Dis Int2003; 2:491-495. (Pubitemid 37441663)
23. Kloeckner R, Otto G, Biesterfeld S, Oberholzer K, Dueber C, Pitton MB. MDCTversus MRI assessment of tumor response after transarterial chemoembolization for the treatment of hepatocellular carcinoma. Cardiovasc Intervent Radiol 2010; 33:532-540.
24. Eisenhauer EA, Therasse P, Bogaerts J, Schwartz LH, Sargent D, Ford R, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer2009; 45:228-247.
25. Woo HY, Jang JW, Choi JY, Bae SH, You CR, Rha SE, et al. Tumor doubling time after initial response to transarterial chemoembolization in patients with hepatocellular carcinoma. Scand J Gastroenterol 2010; 45:332-339.
26. Caturelli E, Siena DA, Fusilli S,Villani MR, Schiavone G, Nardella M, etal. Transcatheter arterial chemoembolization for hepatocellular carcinoma in patients with cirrhosis: evaluation of damage to nontumorous liver tissue-long-term prospective study. Radiology2000; 215:123-128. (Pubitemid 30190520)
27. Dhanasekaran R, Kooby DA, Staley CA, Kauh JS, Khanna V, Kim HS. Prognostic factors for survival in patients with unresectable hepatocellular carcinoma undergoing chemoembolization with doxorubicin drug-eluting beads: a preliminary study. HPB 2010; 12:174-180.
28. Brown DB, Fundakowski CE, Lisker-Melman M, Crippin JS, Pilgram TK, Chapman W, etal. Comparison of MELD and Child-Pugh scores to predict survival after chemoembolization for hepatocellular carcinoma. J Vasc Interv Radiol2004; 15:1209-1218. (Pubitemid 39487850)
29. Malagari K, Chatzimichael K, Alexopoulou E, Kelekis A, Hall B, Dourakis S, et al. Transarterial chemoembolization of unresectable hepatocellular carcinoma with drug eluting beads: results of an open-label study of 62 patients. Cardiovasc Intervent Radiol 2008; 31:269-280.
30. Nouso K, Ito YM, Kuwaki K, Kobayashi Y, Nakamura S, Ohashi Y, et al. Prognostic factors and treatment effects for hepatocellular carcinoma in Child C cirrhosis. Br J Cancer 2008; 98:1161-1165. (Pubitemid 351481668)
31. Sacco R, Bertini M, Petruzzi P, Bertoni M, Bargellini I, Bresci G, etal. Clinical impact of selective transarterial chemoembolization on hepatocellular carcinoma: a cohort study. WorldJ Gastroenterol 2009; 15:1843-1848.